| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 107,012 | 17,104 |
| Deferred income taxes | 4,072 | -877 |
| Amortization of capitalized fees and depreciation of property and equipment | 10,464 | 6,976 |
| Amortization of acquired intangible assets | 19,640 | 13,022 |
| Inventory fair value step-up adjustment included in cost of products sold | 4,109 | 625 |
| Stock-based compensation | 6,949 | 4,569 |
| Amortization of debt discount and issuance costs | 1,533 | 1,078 |
| Changes in fair values of equity method investments, net | 30,284 | -467 |
| Changes in fair values of equity and long-term investments, net | -22,509 | -54,019 |
| Acquired in-process research and development assets | 9,368 | - |
| Other non-cash items | -402 | -423 |
| Accounts receivable | 9,775 | 533 |
| Receivables from collaboration arrangement | -2,622 | 1,362 |
| Inventory | 10,299 | 17,146 |
| Prepaid expenses | -1,648 | -4,453 |
| Other assets | -1,001 | -774 |
| Accounts payable | 4,111 | 3,250 |
| Accrued personnel-related expenses and other accrued liabilities | -14,568 | 1,932 |
| Accrued interest payable | -3,191 | -4 |
| Income tax payable | 2,649 | 1,921 |
| Deferred revenue | 12,445 | 1,999 |
| Net cash provided by operating activities | 142,417 | 92,690 |
| Purchases of trading securities | 49,674 | 34,674 |
| Proceeds from trading securities | 5,097 | 5,097 |
| Purchases of equity investments managed by isp fund lp | 0 | 0 |
| Sales of equity investments managed by isp fund lp | 19,939 | 19,939 |
| Purchases and sales of other investments managed by isp fund lp, net | -51,987 | -8,086 |
| Purchases of property and equipment | 1,121 | - |
| Cash paid for in-process research and development assets acquired | 9,368 | - |
| Sale of property and equipment | 0 | 0 |
| Net cash provided by (used in) investing activities | 16,860 | -1,552 |
| Repurchase of common stock | 0 | 0 |
| Repurchase of shares to satisfy tax withholding | 116 | 91 |
| Proceeds from issuances of common stock, net | 1,715 | 1,521 |
| Proceeds from exercise of warrants | 10,698 | - |
| Payment for repurchase of convertible subordinated notes due 2025 | 25 | - |
| Net cash provided by (used in) financing activities | 12,272 | 1,430 |
| Net increase in cash and cash equivalents | 171,549 | 92,568 |
| Cash and cash equivalents at beginning of period | 304,964 | - |
| Cash and cash equivalents at end of period | 476,513 | - |
Innoviva, Inc. (INVA)
Innoviva, Inc. (INVA)